EpilepsyNCT07854093
Impact of Epilepsy on Motor Function, Fatigue, and Quality of Life
An observational study of Epilepsy, run by Borna Farhoomand.
Trial summary
Epilepsy is a chronic neurological disorder that can significantly affect a person's physical abilities and daily life due to the condition itself and the side effects of anti-epileptic medications. Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Epilepsy
- What is being tested?
- Functional and Quality of Life Assessments
- How many people
- 40 participants
- Where
- No sites listed yet
- Study dates
- 1 Oct 2026to 28 Jan 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Adult
Study population: Participants will be selected from adult patients presenting to the neurology outpatient clinic diagnosed with epilepsy, alongside a cohort of healthy volunteers recruited from the local community and hospital staff to serve as the control group.
Who may be able to join
- Diagnosed with epilepsy by a neurologist (for the patient group),
- No history of neurological, orthopedic, or vestibular disorders other than epilepsy (for the patient group),
- Being a healthy individual with no history of chronic medical, neurological, or musculoskeletal conditions (for the control group),
- Ability to understand and follow verbal instructions,
- Voluntarily agreed to participate and signed the informed consent form.
Who cannot join
- Presence of any acute musculoskeletal injury, fracture, or severe lower extremity surgery within the past 6 months,
- History of acute vestibular disorders, vertigo, or balance impairments unrelated to epilepsy,
- Severe visual or auditory impairments that cannot be corrected and would affect testing performance,
- Pregnancy or suspected pregnancy,
- Presence of severe psychiatric disorders or cognitive impairment that prevents participation in functional and questionnaire-based assessments.
About this study
Official title: The Impact of Epilepsy on Motor Function, Fatigue, and Quality of Life.
Epilepsy is a chronic neurological disorder that can significantly affect a person's physical abilities and daily life due to the condition itself and the side effects of anti-epileptic medications. Individuals with epilepsy often experience fatigue, changes in balance, decreased muscle strength, and reduced mobility, which can restrict their activities of daily living and lead to a decline in their overall quality of life.The primary purpose of this observational study is to comprehensively evaluate the functional status and quality of life in individuals diagnosed with epilepsy. To accurately measure these impacts, the study will compare the physical performance, balance, and fatigue levels of epilepsy patients to a healthy control group.The main question this study attempts to answer is: How do functional mobility, balance, fatigue, and quality of life in individuals with epilepsy differ from those of healthy individuals without the condition?By identifying these physical and functional challenges, researchers aim to better understand the relationship between physical capacity and quality of life in this population. Ultimately, the research findings will guide the future development of targeted physiotherapy and rehabilitation programs designed to improve the functional independence and quality of life for individuals living with epilepsy.
- Conditions
- Epilepsy
- Being tested
- Functional and Quality of Life Assessments
- Medical subject headings
- Epilepsy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Functional and Quality of Life AssessmentsOther
Participants will undergo a single-session assessment battery evaluating physical performance, cognition, fatigue, and quality of life. Assessments include: Quality of Life in Epilepsy (QOLIE-10); Modified Fatigue Impact Scale (MFIS); Neurological Disorders Depression Inventory for Epilepsy (NDDI-E); Timed Up and Go (TUG), 3-meter Backward Walk Test (3mBWT), and 30-Second Chair Stand Test (30-STS) for mobility and lower extremity strength; 9-Hole Peg Test (9HPT) for upper extremity dexterity; Paced Auditory Serial Addition Test (PASAT-3) for cognitive processing; and the SportKAT 550® system for objective dynamic balance evaluation. These tests are purely observational (non-therapeutic) and are administered once to both the epilepsy patient group and the healthy control group to compare functional status.
| Study group | Role | What they receive |
|---|---|---|
| Epilepsy Group | Not described Receives: Other: Functional and Quality of Life Assessments | |
| Healthy Control Group | Not described Receives: Other: Functional and Quality of Life Assessments |
What is being measured
The primary outcome is the main question the study is designed to answer.
Upper Extremity Dexterity as Assessed by the 9-Hole Peg Test (9HPT).
Measured: Baseline
Objective Dynamic Balance Performance as Assessed by the SportKAT 550 System.
Measured: Baseline
Mobility as Assessed by the Timed Up and Go (TUG) Test.
Measured: Baseline.
Dynamic Balance and Mobility as Assessed by the 3-meter Backward Walk Test (3mBWT).
Measured: Baseline
Lower Extremity Strength and Endurance as Assessed by the 30-Second Chair Stand Test (30-STS).
Measured: Baseline
Secondary outcomes (4)
Quality of Life Score as Assessed by the Quality of Life in Epilepsy-10 (QOLIE-10)
Measured: Baseline.
Fatigue Severity as Assessed by the Modified Fatigue Impact Scale (MFIS).
Measured: Baseline.
Cognitive Processing Speed as Assessed by the Paced Auditory Serial Addition Test (PASAT-3).
Measured: Baseline.
Depression Severity as Assessed by the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E).
Measured: Baseline.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Oct 2026
- Study start1 Oct 2026 (estimated)
- Primary completion25 Dec 2026 (estimated)
- Study completion28 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EpilepsyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Borna Farhoomand
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Borna Farhoomand, Pamukkale University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07854093
- Sponsor's protocol ID
- E-60116787-020-684112
- Status last verified
- Sep 2026
- First submitted
- 26 Sep 2026
- Last updated
- 2 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Impact of Epilepsy on Motor Function, Fatigue, and Quality of Life.
- ClinicalTrials.gov ID
- NCT07854093
- Acronym / sponsor ID
- E-60116787-020-684112
- Conditions
- Epilepsy
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Borna FarhoomandUniversity, hospital or other
- Study start
- 1 Oct 2026 (estimated)
- Primary completion
- 25 Dec 2026 (estimated)
- Study completion
- 28 Jan 2027 (estimated)
- First posted
- 2 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Epilepsy is a chronic neurological disorder that can significantly affect a person's physical abilities and daily life due to the condition itself and the side effects of anti-epileptic medications. Individuals with epilepsy often experience fatigue, changes in balance, decreased muscle strength, and reduced mobility, which can restrict their activities of daily living and lead to a decline in their overall quality of life.The primary purpose of this observational study is to comprehensively evaluate the functional status and quality of life in individuals diagnosed with epilepsy. To accurately measure these impacts, the study will compare the physical performance, balance, and fatigue levels of epilepsy patients to a healthy control group.The main question this study attempts to answer is: How do functional mobility, balance, fatigue, and quality of life in individuals with epilepsy differ from those of healthy individuals without the condition?By identifying these physical and functional challenges, researchers aim to better understand the relationship between physical capacity and quality of life in this population. Ultimately, the research findings will guide the future development of targeted physiotherapy and rehabilitation programs designed to improve the functional independence and quality of life for individuals living with epilepsy.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Epilepsy Group | – | Other: Functional and Quality of Life Assessments |
| Healthy Control Group | – | Other: Functional and Quality of Life Assessments |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Age groups
- Adult
- Study population
- Participants will be selected from adult patients presenting to the neurology outpatient clinic diagnosed with epilepsy, alongside a cohort of healthy volunteers recruited from the local community and hospital staff to serve as the control group.
Key inclusion criteria (5 listed)
- Diagnosed with epilepsy by a neurologist (for the patient group),
- No history of neurological, orthopedic, or vestibular disorders other than epilepsy (for the patient group),
- Being a healthy individual with no history of chronic medical, neurological, or musculoskeletal conditions (for the control group),
- Ability to understand and follow verbal instructions,
- Voluntarily agreed to participate and signed the informed consent form.
Key exclusion criteria (5 listed)
- Presence of any acute musculoskeletal injury, fracture, or severe lower extremity surgery within the past 6 months,
- History of acute vestibular disorders, vertigo, or balance impairments unrelated to epilepsy,
- Severe visual or auditory impairments that cannot be corrected and would affect testing performance,
- Pregnancy or suspected pregnancy,
- Presence of severe psychiatric disorders or cognitive impairment that prevents participation in functional and questionnaire-based assessments.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Functional and Quality of Life AssessmentsParticipants will undergo a single-session assessment battery evaluating physical performance, cognition, fatigue, and quality of life. Assessments include: Quality of Life in Epilepsy (QOLIE-10); Modified Fatigue Impact Scale (MFIS); Neurological Disorders Depression Inventory for Epilepsy (NDDI-E); Timed Up and Go (TUG), 3-meter Backward Walk Test (3mBWT), and 30-Second Chair Stand Test (30-STS) for mobility and lower extremity strength; 9-Hole Peg Test (9HPT) for upper extremity dexterity; Paced Auditory Serial Addition Test (PASAT-3) for cognitive processing; and the SportKAT 550® system for objective dynamic balance evaluation. These tests are purely observational (non-therapeutic) and are administered once to both the epilepsy patient group and the healthy control group to compare functional status. | Other | Epilepsy Group, Healthy Control Group |
Primary outcome
Upper Extremity Dexterity as Assessed by the 9-Hole Peg Test (9HPT).
Time frame: Baseline
Objective Dynamic Balance Performance as Assessed by the SportKAT 550 System.
Time frame: Baseline
Mobility as Assessed by the Timed Up and Go (TUG) Test.
Time frame: Baseline.
Dynamic Balance and Mobility as Assessed by the 3-meter Backward Walk Test (3mBWT).
Time frame: Baseline
Lower Extremity Strength and Endurance as Assessed by the 30-Second Chair Stand Test (30-STS).
Time frame: Baseline
4 secondary outcomes
Quality of Life Score as Assessed by the Quality of Life in Epilepsy-10 (QOLIE-10)
Time frame: Baseline.
Fatigue Severity as Assessed by the Modified Fatigue Impact Scale (MFIS).
Time frame: Baseline.
Cognitive Processing Speed as Assessed by the Paced Auditory Serial Addition Test (PASAT-3).
Time frame: Baseline.
Depression Severity as Assessed by the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E).
Time frame: Baseline.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Oct 2026.
Related trials for Epilepsy
Not yet recruiting
Clinical Trial of SEEG for Drug-resistant Epilepsy
Drug-Resistant Epilepsy
RecruitingPhase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
Seizures, Lennox Gastaut Syndrome
RecruitingPhase 3
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
Focal Seizure, Epilepsy
Active, not recruitingObservational study
Transforming Research and Clinical Knowledge in Traumatic Brain Injury Epileptogenesis Project (TRACK-TBI EPI)
Traumatic Brain Injury, Post-traumatic Epilepsy
RecruitingPhase 3
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
Focal Seizure, Epilepsy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Epilepsy, run by Borna Farhoomand.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Upper Extremity Dexterity as Assessed by the 9-Hole Peg Test (9HPT). (time frame: Baseline). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2026.